Systemic reactions to ophthalmic drug preparations

Area of Science:

• Ophthalmology
• Pharmacology
• Systemic Drug Reactions

Background:

• Topical ophthalmic medications are widely used for various ocular conditions.
• Systemic absorption of ophthalmic drugs can lead to adverse effects.
• Understanding these risks is crucial for safe clinical practice.

Purpose of the Study:

• To survey adverse systemic reactions associated with topical ophthalmic timolol, chloramphenicol, phenylephrine, and cyclopentolate.
• To emphasize precautions and contraindications for these ophthalmic drug preparations.

Main Methods:

• Review of literature on systemic adverse reactions of specified ophthalmic drugs.
• Analysis of case reports and clinical studies detailing systemic effects.
• Identification of patient populations and drug combinations requiring caution.

Main Results:

• Timolol (beta-adrenergic antagonist) requires caution in patients with respiratory or cardiovascular conditions, or those on systemic beta-blockers/verapamil.
• Topical chloramphenicol is associated with blood dyscrasias; use is restricted to resistant organisms.
• Phenylephrine (2.5% and 10%) can cause cardiovascular effects, especially in patients on MAOIs, TCAs, atropine, or with pre-existing cardiovascular risk factors.
• Cyclopentolate-induced central nervous system toxicity is dose-dependent and preventable with minimal concentrations and reduced administration frequency.
• Nasolacrimal occlusion post-instillation reduces systemic drug absorption.

Conclusions:

• Systemic absorption of topical ophthalmic drugs necessitates careful consideration of patient history and concurrent medications.
• Specific precautions and contraindications exist for timolol, chloramphenicol, phenylephrine, and cyclopentolate.
• Techniques like nasolacrimal occlusion can significantly mitigate systemic adverse effects.